Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 11/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7260048 | 0.93 | MMP1 (0.44) | MMP1MMP2MMP9MMP12EGFR | |
| SCHEMBL5050337 | 0.83 | MMP1 (0.38) | MMP1MMP2MMP9MMP12EGFR | |
| SCHEMBL5048998 | 0.81 | RAB9A (0.38) | ALDH1A1CYP3A4 | |
| SCHEMBL7263882 | 0.76 | MMP1 (0.47) | MMP1MMP2MMP9MMP12EGFR | |
| SCHEMBL7263120 | 0.74 | ALDH1A1 (0.40) | ALDH1A1TSHRHSD17B10CYP3A4 | |
| SCHEMBL8164747 | 0.73 | MMP1 (0.49) | MMP1MMP2MMP9MMP12EGFR | |
| SCHEMBL5050210 | 0.69 | CYP4F2 (0.44) | MMP1MMP2MMP9MMP12ALDH1A1 | |
| SCHEMBL5050338 | 0.69 | CYP19A1 (0.41) | MMP1MMP2MMP9MMP12ALDH1A1 | |
| SCHEMBL15457003 | 0.68 | CYP19A1 (0.42) | MMP2MMP9CACNA1BCYP19A1CYP3A4 | |
| SCHEMBL19462887 | 0.67 | APP (0.44) | MMP1MMP2MMP9MMP12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | claimed |
| WO-2023154784-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULE | MACROGENICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. | 2023-07-20 | — | — | US | claimed |
| EP-4149549-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MacroGenics, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-11591400-B2 | B7-H3 directed antibody drug conjugates | MACROGENICS, INC. (US) | 2023-02-28 | — | — | US | claimed |
| WO-2021231309-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| US-20210171641-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. | 2021-06-10 | — | — | US | claimed |
| US-10961311-B2 | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof | MACROGENICS, INC. (US) | 2021-03-30 | — | — | US | claimed |
| US-20190127471-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. | 2019-05-02 | — | — | US | claimed |
| EP-3442574-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MacroGenics, Inc. (US) | 2019-02-20 | — | — | EP | claimed |
| WO-2017180813-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2017-10-19 | — | — | WO | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023154784-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULE | MACROGENICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | disclosed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | disclosed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | CD274, CD2, CD22 | MMP1 4532/4885MMP2 3725/4885MMP9 4485/4885 |
| US-11591400-B2 | B7-H3 directed antibody drug conjugates | CD274, CD2, CD22 | MMP1 4532/4885MMP2 3725/4885MMP9 4485/4885 |
| US-10961311-B2 | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof | CD274, HRH3, CD2 | MMP1 4605/4885MMP2 3663/4885MMP9 4452/4885 |
| US-20190127471-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | CD274, CD2, CD22 | MMP1 4610/4885MMP2 3722/4885MMP9 4496/4885 |
| US-20210171641-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | CD274, CD2, CD22 | MMP1 4610/4885MMP2 3722/4885MMP9 4496/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | MMP1 685/4885MMP2 720/4885MMP9 758/4885 |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | CD274, PDCD1, H1-3 | MMP1 3262/4885MMP2 3399/4885MMP9 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.